ASX Announcements, Company News, Evidence 02 Dec 2024 Orthocell successfully completes US FDA 510(k) regulatory study for Remplir™ Orthocell has today reached another significant milestone with the successful completion of its Remplir™ 510(k) nerve repair regulatory study, validating… Orthocell
Company News, Evidence 18 Apr 2023 Commencement of Nerve Repair Study Orthocell (ASX:OCC) has announced the commencement of a nerve repair study aimed at supporting product marketing initiatives and international regulatory… Orthocell
